SH003 represses tumor angiogenesis by blocking VEGF binding to VEGFR2 SCIE SCOPUS
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Choi, Hyeong Sim | - |
dc.contributor.author | Kim, Min Kyoung | - |
dc.contributor.author | Lee, Kangwook | - |
dc.contributor.author | Lee, Kang Min | - |
dc.contributor.author | Choi, Youn Kyung | - |
dc.contributor.author | Shin, Yong Cheol | - |
dc.contributor.author | Cho, Sung-Gook | - |
dc.contributor.author | Ko, Seong-Gyu | - |
dc.date.accessioned | 2020-04-20T02:55:12Z | - |
dc.date.available | 2020-04-20T02:55:12Z | - |
dc.date.created | 2020-01-28 | - |
dc.date.issued | 2016-05 | - |
dc.identifier.issn | 1949-2553 | - |
dc.identifier.uri | https://sciwatch.kiost.ac.kr/handle/2020.kiost/2273 | - |
dc.description.abstract | Tumor angiogenesis is a key feature of cancer progression, because a tumor requires abundant oxygen and nutrition to grow. Here, we demonstrate that SH003, a mixed herbal extract containing Astragalus membranaceus (Am), Angelica gigas (Ag) and Trichosanthes Kirilowii Maximowicz (Tk), represses VEGF-induced tumor angiogenesis both in vitro and in vivo. SH003 inhibited VEGF-induced migration, invasion and tube formation in human umbilical vein endothelial cells (HUVEC) with no effect on the proliferation. SH003 reduced CD31-positive vessel numbers in tumor tissues and retarded tumor growth in our xenograft mouse tumor model, while SH003 did not affect pancreatic tumor cell viability. Consistently, SH003 inhibited VEGF-stimulated vascular permeability in ears and back skins. Moreover, SH003 inhibited VEGF-induced VEGFR2-dependent signaling by blocking VEGF binding to VEGFR2. Therefore, our data conclude that SH003 represses tumor angiogenesis by inhibiting VEGF-induced VEGFR2 activation, and suggest that SH003 may be useful for treating cancer. | - |
dc.description.uri | 1 | - |
dc.language | English | - |
dc.publisher | IMPACT JOURNALS LLC | - |
dc.title | SH003 represses tumor angiogenesis by blocking VEGF binding to VEGFR2 | - |
dc.type | Article | - |
dc.citation.endPage | 32979 | - |
dc.citation.startPage | 32969 | - |
dc.citation.title | ONCOTARGET | - |
dc.citation.volume | 7 | - |
dc.citation.number | 22 | - |
dc.contributor.alternativeName | 최윤경 | - |
dc.identifier.bibliographicCitation | ONCOTARGET, v.7, no.22, pp.32969 - 32979 | - |
dc.identifier.doi | 10.18632/oncotarget.8808 | - |
dc.identifier.scopusid | 2-s2.0-84973572497 | - |
dc.identifier.wosid | 000377748500105 | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.isOpenAccess | N | - |
dc.subject.keywordPlus | TRADITIONAL CHINESE MEDICINE | - |
dc.subject.keywordPlus | ANGELICA-GIGAS NAKAI | - |
dc.subject.keywordPlus | ASTRAGALUS-MEMBRANACEUS | - |
dc.subject.keywordPlus | CANCER-TREATMENT | - |
dc.subject.keywordPlus | ASIAN MEDICINE | - |
dc.subject.keywordPlus | CHEMOTHERAPY | - |
dc.subject.keywordPlus | DECURSIN | - |
dc.subject.keywordPlus | COMBINATION | - |
dc.subject.keywordPlus | MECHANISMS | - |
dc.subject.keywordPlus | THERAPY | - |
dc.subject.keywordAuthor | SH003 | - |
dc.subject.keywordAuthor | tumor angiogenesis | - |
dc.subject.keywordAuthor | VEGF | - |
dc.subject.keywordAuthor | VEGFR2 | - |
dc.subject.keywordAuthor | TCM | - |
dc.relation.journalWebOfScienceCategory | Oncology | - |
dc.relation.journalWebOfScienceCategory | Cell Biology | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Oncology | - |
dc.relation.journalResearchArea | Cell Biology | - |